Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019
01 November 2019 - 7:43AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that it will report its third quarter 2019 financial results on
Monday, November 4, 2019. Management will host a conference call
and live audio webcast to discuss these results and provide a
corporate update at 4:30 p.m. EST.
To participate in the conference call, please dial
1-844-646-4465 (domestic) or 1-615-247-0257 (international) and
reference the access code 3482317. The live webcast can be accessed
under “News & Events” in the Investors section of the Company’s
website at www.iovance.com or at the link:
https://edge.media-server.com/mmc/p/9ohu47kv.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to improve patient care by
making T cell-based immunotherapies broadly accessible for the
treatment of patients with solid tumors and blood cancers. Tumor
infiltrating lymphocyte (TIL) therapy uses a patient’s own immune
cells to attack cancer. TIL cells are extracted from a patient’s
own tumor tissue, expanded through a proprietary process, and
infused back into the patient. After infusion, TIL reach tumor
tissue, where they attack tumor cells. The company is currently
conducting pivotal studies in patients with metastatic melanoma and
advanced cervical cancer. In addition, the company’s TIL therapies
are being investigated for the treatment of patients with locally
advanced, recurrent or metastatic cancers including head and neck
and non-small cell lung cancer. Clinical studies of T cell therapy
for blood cancers called peripheral blood lymphocyte (PBL) therapy
are being planned. For more information, please visit
www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics,
Inc. (hereinafter referred to as the “Company,” “we,” “us,” or
“our”). We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. The
forward-looking statements include, but are not limited to, risks
and uncertainties relating to the success, timing, projected
enrollment, manufacturing and production capabilities, and cost of
our ongoing clinical trials and anticipated clinical trials for our
current product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe),
such as statements regarding the timing of initiation and
completion of these trials; the timing of and our ability to
successfully submit, obtain and maintain FDA or other
regulatory authority approval of, or other action with respect to,
our product candidates, including those product candidates that
have been granted breakthrough therapy designation (“BTD”) or
regenerative medicine advanced therapy designation (“RMAT”) by
the FDA and new product candidates in both solid tumor
and blood cancers; the strength of the Company’s product pipeline;
the successful implementation of the Company’s research and
development programs and collaborations; the Company’s ability to
obtain tax incentives and credits; the guidance provided for the
Company’s future cash, cash equivalent, and short term investment
positions; the success of the Company’s manufacturing, license or
development agreements; the acceptance by the market of the
Company’s product candidates, if approved; and other factors,
including general economic conditions and regulatory developments,
not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially
different from those expressed in or implied by such statements.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in the
Company’s business, including, without limitation: the preliminary
clinical results, which may include efficacy and safety results,
from ongoing Phase 2 studies may not be reflected in the final
analyses of these trials; the rate of enrollment may impact the
Company’s clinical trial timelines; enrollment may need to be
adjusted for the Company’s trials and cohorts within those trials
based on FDA and other regulatory agency input; the new
version of the protocol which further defines the patient
population to include more advanced patients in the Company’s
cervical cancer trial may have an adverse effect on the results
reported to date; the data within these trials may not be
supportive of product approval; changes in patient populations may
result in changes in preliminary clinical results; the Company’s
ability to address FDA or other regulatory authority
requirements relating to its clinical programs and registrational
plans, such requirements including, but not limited to, clinical,
safety, manufacturing and control requirements; the Company’s
interpretation of communications with the FDA; risks related
to the Company’s ability to maintain and benefit from
accelerated FDA review designations, including BTD and
RMAT, which may not result in a faster development process or
review of the Company’s product candidates (and which may later be
rescinded by the FDA), and does not assure approval of such
product candidates by the FDA or the ability of the
Company to obtain FDA approval in time to benefit from
commercial opportunities; and the ability of the Company to
manufacture its therapies using third party manufacturers. A
further list and description of the Company’s risks, uncertainties
and other factors can be found in the Company’s most recent Annual
Report on Form 10-K and the Company’s subsequent filings with
the Securities and Exchange Commission. Copies of these
filings are available online
at www.sec.gov or www.iovance.com. The
forward-looking statements are made only as of the date of this
press release and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024